Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

• Julie Terzic,
• Amanda Seipel,
• Jean Dubuisson,
• Jean-Christophe Tille,
• Petros Tsantoulis,
• Alfredo Addeo,
• S.Intidhar Labidi-Galy

Affiliations

Julie Terzic

Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland

Amanda Seipel

Department of Diagnosis, Division of Clinical Pathology, Hôpitaux Universitaires de Genève, Genève, Switzerland

Jean Dubuisson

Department of Woman, Child and Adolescent, Division of Gynecology, Hôpitaux Universitaires de Genève, Genève, Switzerland

Jean-Christophe Tille

Department of Diagnosis, Division of Clinical Pathology, Hôpitaux Universitaires de Genève, Genève, Switzerland

Petros Tsantoulis

Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland; Department of Medicine, Faculty of Medicine, University of Geneva, Genève, Switzerland

Alfredo Addeo

Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland

S.Intidhar Labidi-Galy

Department of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland; Department of Medicine, Faculty of Medicine, University of Geneva, Genève, Switzerland; Corresponding author at: Department of Oncology, Hôpitaux Universitaires de Genève, Rue Gabrielle Perret-Gentil 4, 1204 Geneva, Switzerland.